Diplomat Announces 2nd Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Leerink Partners Raises price Target on Diplomat Pharmacy (DPLO) to $38 Following Mixed 2Q
August 10, 2016 7:07 AM EDTLeerink Partners reiterated an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and raised the price target to $38.00 (from $36.00), following the company's 2Q earnings report. DPLO reported total revenue of $1,089M, 3% below consensus of $1,118M. Adjusted EPS $0.23 was above the consensus estimates of $0.21.
Analyst... More
Diplomat Pharmacy (DPLO) Tops Q2 EPS by 2c
August 9, 2016 4:40 PM EDTDiplomat Pharmacy (NYSE: DPLO) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.12 billion.
GUIDANCE:
Diplomat Pharmacy sees FY2016 EPS of $0.90-$0.95, versus prior guidance of... More
